Secretary of Department of Pharmaceuticals, PD Vaghela has said that the central government will shortly unveil a new Research and Development (R&D) policy for pharma & medical device sector. He said the new R&D policy will seek to focus on benchmarking the R&D ecosystem, coordination among research institutes and recognising scientists. Besides, he said the government is planning to set up three National Centres of Excellence (CoE) for drugs, medical devices in the country while the National Institute of Pharmaceutical Education and Research (NIPER) will house one CoE for drug discovery.
According to Vaghela, India's pharma industry is the third largest in the world in terms of volume and stands 14th in terms of value even as it contributes 3.5 percent of the total medicines exported globally. He also indicated that the total size of pharma and related industry including medical devices in the country was at $51 billion in 2019- 20, of which 75 percent is contributed by pharmaceutical products alone.
Noting that India faces three challenges in the pharma and medical devices sectors, he said 86 percent of the total requirement of medical devices including surgical, cardiac stents and electronic gadgets are currently being imported due to cost advantage. He also noted that the other two challenges are import dependence for drug intermediates and Active Pharmaceutical Ingredients (API) while the third was R&D in the healthcare and pharmaceutical sector and skilling. He added that the central government was proposing to set up three bulk drug parks, for which it provides Rs 1,000 crore to each.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: